coxib


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

coxib

(kok'ib),
Shortened colloquial name for the cyclooxygenase-2 inhibitors; all members of that groups' names end in the suffix "coxib."

coxib

(kŏk′sĭb)
Any nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation by inhibiting cyclooxygenase-2 (COX-2) but not cyclooxygenase-1 (COX-1). Most NSAIDs (e.g., celecoxib) inhibit both COX-2 and COX-1. Selective inhibition prevents the coxibs from forming prostaglandins, which irritate the upper gastrointestinal tract.
References in periodicals archive ?
In particular, the rate of hip, pelvis, wrist, or humerus fractures was 101 per 1,000 person-years in the opioid group, compared with 19 per 1,000 person-years in the coxib group and 26 per 1,000 person-years in the NSAID group.
01) for patients treated with coxibs (alone or in addition to tNSAIDs or glucocorticoids), and 3.
This helped illuminate the role that all NSAIDs--even coxibs like celecoxib (Celebrex[R]) and valdecoxib (Bextra[R])--may play in hypervolemic hyponatremia among endurance athletes.
76), but a lower risk was observed for coxib users (HR, 0.
Last column refers to number of patients that need to be treated with a coxib for a year to prevent 1 upper GI complication, except where not applicable.
Celecoxib is the first coxib product to target only the COX-2 enzyme.
Following FDA approval for the acute treatment of migraine in late March, VIOXX is now approved for treating more types of painful conditions than any other coxib in the United States and remains the only coxib approved to relieve migraine pain and associated migraine symptoms.
Even more interesting, in a high-risk patient with a history of ulcer bleeding, 60% said they would recommend a proton pump inhibitor with a coxib and aspirin--even though there are no published data to support this strategy, and 24%, disturbingly, would choose a coxib and aspirin without gastroprotection," Dr.
Bob joins us at an exciting juncture as we build on the leadership position we have established in the coxib arena with this year's launches of Bextra and Dynastat.
No coxib in the United States currently has indications for chronic low-back pain, acute gouty arthritis or ankylosing spondylitis.
But experts sharply disagree on whether the findings on this latest addition to the class of selective cyclo-oxygenase 2 (COX-2) inhibitors truly exonerate the coxib of its role in potentiating myocardial infarctions and gastrointestinal adverse effects.